The FDA approved the osteoporosis drug Evista for the prevention of invasive breast cancer in some groups of high-risk women, drugmaker Eli Lilly & Co. announced Friday. Evista, or raloxifene, has been shown to reduce the risk of breast cancer among postmenopausal women with osteoporosis and among postmenopausal women at high risk for breast cancer by 44%; however, it also had been found to increase their risks for blood clots and stroke.

Full Story:

Related Summaries